AIM: To investigate the efficacy of moxibustion in ulcerative colitis (UC) rats from morphological, immunological and molecular biological perspectives. METHODS: Thirty-two Sprague-Dawley rats were randomly assigned t...AIM: To investigate the efficacy of moxibustion in ulcerative colitis (UC) rats from morphological, immunological and molecular biological perspectives. METHODS: Thirty-two Sprague-Dawley rats were randomly assigned to a blank control group (normal rats, n = 6) and a model replication (MR) group (UC rats, n = 26). A UC model was established by 2,4,6-trinitrobenzenesulfonic acid/dextran sulfate sodium enema. Rats in the MR group were further randomly assigned to a 9-min moxibustion (9M) group (9 moxa-cone, n = 6), 6-min moxibustion (6M) group (6 moxa-cone, n = 6), 3-min moxibustion (3M) group (3 moxa-cone, n = 6), and a waiting list control (WLC) group (no moxibustion treatment, n = 6). Rats in the moxibustion treatment group were treated in 14 sessions over 28 d. Disease activity, local tissue morphology, serum level of interleukin (IL)-8 and IL-10, and expression of Toll-like receptor (TLR)9 as well as nuclear factor (NF)-kappa B p65 in colonic tissue were determined by disease activity index (DAI), hematoxylin and eosin staining, electron microscopy, enzyme-linked immunosorbent assay and Western blotting, respectively. RESULTS: DAI was lowest in the 9M group and highest in the WLC group. The differences in DAI between the moxibustion treatment (3M, 6M, 9M) and no treatment groups were significant for all one-to-one comparisons (0.60 +/- 0.54 vs 1.20 +/- 0.44, 0.60 +/- 0.54 vs 1.80 +/- 0.45, 0.60 +/- 0.54 vs 3.0 +/- 0.45, respectively, P < 0.05). Light and electron microscopy showed that the neatness of the glandular arrangement in colonic mucosal epithelia gradually increased in the WLC, 3M, 6M to 9M groups. IL-8 level successively decreased while IL-10 level increased from the WLC to 3M, 6M and 9M groups. The differences among these groups were significant for all comparisons (105.46 +/- 8.75 vs 76.61 +/- 3.58, 105.46 +/- 8.75 vs 69.78 +/- 1.87, 105.46 +/- 8.75 vs 67.41 +/- 1.84, respectively, P < 0.01 for IL-8; and 30.83 +/- 1.29 vs 75.64 +/- 1.90, 30.83 +/- 1.29 vs 80.90 +/- 3.16, 30.83 +/- 1.29 vs 83.46 +/-展开更多
目的观察美沙拉秦栓1次/d与2次/d给药治疗轻中度活动期溃疡性直肠炎的疗效及安全性。方法本试验为随机、非劣效性研究。选取2013年10月—2015年6月济南军区总医院符合纳入与排除标准的轻中度活动期溃疡性直肠炎患者82例,采用随机数字表...目的观察美沙拉秦栓1次/d与2次/d给药治疗轻中度活动期溃疡性直肠炎的疗效及安全性。方法本试验为随机、非劣效性研究。选取2013年10月—2015年6月济南军区总医院符合纳入与排除标准的轻中度活动期溃疡性直肠炎患者82例,采用随机数字表将其分为A组(n=41)和B组(n=41)。A组给予美沙拉秦栓1.0g/次,晚睡前便后纳肛,1次/d;B组给予美沙拉秦栓0.5 g/次,便后纳肛,早、晚各1次。两组均给药8周。采用疾病活动指数(DAI)评价疾病活动程度。以治疗第8周时DAI评分作为主要疗效指标;以治疗第8周时DAI各分项评分(大便次数、大便带血、黏膜炎症、总体评价)及临床缓解率作为次要疗效指标,并记录两组不良反应发生情况。结果患者均完成8周治疗。两组治疗前后DAI评分比较,差异均有统计学意义(P<0.001);两组间治疗前及治疗第8周DAI评分比较,差异均无统计学意义(P>0.05)。A组治疗第8周时DAI评分-B组治疗第8周时DAI评分(U1-U2)双侧95%可信区间(-0.33,0.87)的下限>-1.00,拒绝无效假设,认为A组的疗效不差于B组。两组治疗8周后大便次数、大便带血、黏膜炎症、整体评价评分均低于治疗前,差异有统计学意义(P<0.05)。治疗前和治疗第8周,两组间大便次数、大便带血、黏膜炎症、整体评价评分比较,差异均无统计学意义(P>0.05)。经过8周治疗后,A、B两组临床缓解率分别为95.1%(39/41)、90.2%(37/41),差异无统计学意义(χ2=0.719,P=0.396)。A组不良反应发生率为48.8%(20/41),B组不良反应发生率为61.0%(25/41),差异无统计学意义(χ2=1.231,P=0.267)。结论在8周的临床试验中,美沙拉秦栓1.0 g 1次/d给药与0.5 g 2次/d给药治疗轻中度活动期溃疡性直肠炎疗效一致,且安全。展开更多
AIM To investigate the changes in microbiota in feces of patients with ulcerative colitis(UC) and pouchitis using genomic technology.METHODS Fecal samples were obtained from UC patients with or without an ileal pouch-...AIM To investigate the changes in microbiota in feces of patients with ulcerative colitis(UC) and pouchitis using genomic technology.METHODS Fecal samples were obtained from UC patients with or without an ileal pouch-anal anastomosis(IPAA) procedure, as well as healthy controls. The touchdown polymerase chain reaction technique was used to amplify the whole V3 region of the 16 S r RNA gene, which was transcribed from DNA extracted from fecal samples. Denaturing gradient gel electrophoresis was used to separate the amplicons. The band profiles and similarity indices were analyzed digitally. The predominant microbiota in different groups was confirmed by sequencing the 16 S rR NA gene. RESULTS Microbial biodiversity in the healthy controls was significantly higher compared with the UC groups(P < 0.001) and IPAA groups(P < 0.001). Compared with healthy controls, the UC patients in remission and those in the mildly active stage, the predominant species in patients with moderately and severely active UC changed obviously. In addition, the proportion of the dominant microbiota, which was negatively correlated with the disease activity of UC(r =-6.591, P < 0.01),was decreased in pouchitis patients. The numbers of two types of bacteria, Faecalibacterium prausnitzii and Eubacterium rectale, were reduced in UC. Patients with pouchitis had an altered microbiota composition compared with UC patients. The microbiota from pouchitis patients was less diverse than that from severely active UC patients. Sequencing results showed that similar microbiota, such as Clostridium perfringens, were shared in both UC and pouchitis.CONCLUSION Less diverse fecal microbiota was present in patients with UC and pouchitis. Increased C. perfringens in feces suggest its role in the exacerbation of UC and pouchitis.展开更多
目的探索复方甘草酸苷注射液联合复方谷氨酰胺肠溶胶囊治疗溃疡性结肠炎的临床疗效。方法选取2014年2月—2017年4月西安市中医医院收治的124例溃疡性结肠炎患者,随机分为对照组和治疗组,每组各62例。对照组口服复方谷氨酰胺肠溶胶囊,4粒...目的探索复方甘草酸苷注射液联合复方谷氨酰胺肠溶胶囊治疗溃疡性结肠炎的临床疗效。方法选取2014年2月—2017年4月西安市中医医院收治的124例溃疡性结肠炎患者,随机分为对照组和治疗组,每组各62例。对照组口服复方谷氨酰胺肠溶胶囊,4粒/次,3次/d。治疗组患者在对照组治疗基础上静脉滴注复方甘草酸苷注射液,20 m L/次加入到生理盐水500 m L中,1次/d。两组患者均连续治疗30 d。观察两组的临床疗效,比较两组腹痛程度、疾病活动指数(DAI)、黏液脓血便消失时间。结果治疗后,对照组和治疗组的总有效率分别为82.26%、96.77%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者腹痛程度评分、DAI指数均较治疗前显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组腹痛程度评分、DAI指数均低于对照组,两组比较差异具有统计学意义(P<0.05);治疗组黏液脓血便消失时间显著短于对照组,两组比较差异具有统计学意义(P<0.05)。结论复方甘草酸苷注射液联合复方谷氨酰胺肠溶胶囊治疗溃疡性结肠炎具有较好的临床疗效,可显著降低腹痛程度,降低DAI指数,具有一定的临床推广应用价值。展开更多
基金Supported by Scientific and Technological Project of Educational Department of Liaoning Province,China,No.L2011166
文摘AIM: To investigate the efficacy of moxibustion in ulcerative colitis (UC) rats from morphological, immunological and molecular biological perspectives. METHODS: Thirty-two Sprague-Dawley rats were randomly assigned to a blank control group (normal rats, n = 6) and a model replication (MR) group (UC rats, n = 26). A UC model was established by 2,4,6-trinitrobenzenesulfonic acid/dextran sulfate sodium enema. Rats in the MR group were further randomly assigned to a 9-min moxibustion (9M) group (9 moxa-cone, n = 6), 6-min moxibustion (6M) group (6 moxa-cone, n = 6), 3-min moxibustion (3M) group (3 moxa-cone, n = 6), and a waiting list control (WLC) group (no moxibustion treatment, n = 6). Rats in the moxibustion treatment group were treated in 14 sessions over 28 d. Disease activity, local tissue morphology, serum level of interleukin (IL)-8 and IL-10, and expression of Toll-like receptor (TLR)9 as well as nuclear factor (NF)-kappa B p65 in colonic tissue were determined by disease activity index (DAI), hematoxylin and eosin staining, electron microscopy, enzyme-linked immunosorbent assay and Western blotting, respectively. RESULTS: DAI was lowest in the 9M group and highest in the WLC group. The differences in DAI between the moxibustion treatment (3M, 6M, 9M) and no treatment groups were significant for all one-to-one comparisons (0.60 +/- 0.54 vs 1.20 +/- 0.44, 0.60 +/- 0.54 vs 1.80 +/- 0.45, 0.60 +/- 0.54 vs 3.0 +/- 0.45, respectively, P < 0.05). Light and electron microscopy showed that the neatness of the glandular arrangement in colonic mucosal epithelia gradually increased in the WLC, 3M, 6M to 9M groups. IL-8 level successively decreased while IL-10 level increased from the WLC to 3M, 6M and 9M groups. The differences among these groups were significant for all comparisons (105.46 +/- 8.75 vs 76.61 +/- 3.58, 105.46 +/- 8.75 vs 69.78 +/- 1.87, 105.46 +/- 8.75 vs 67.41 +/- 1.84, respectively, P < 0.01 for IL-8; and 30.83 +/- 1.29 vs 75.64 +/- 1.90, 30.83 +/- 1.29 vs 80.90 +/- 3.16, 30.83 +/- 1.29 vs 83.46 +/-
文摘目的观察美沙拉秦栓1次/d与2次/d给药治疗轻中度活动期溃疡性直肠炎的疗效及安全性。方法本试验为随机、非劣效性研究。选取2013年10月—2015年6月济南军区总医院符合纳入与排除标准的轻中度活动期溃疡性直肠炎患者82例,采用随机数字表将其分为A组(n=41)和B组(n=41)。A组给予美沙拉秦栓1.0g/次,晚睡前便后纳肛,1次/d;B组给予美沙拉秦栓0.5 g/次,便后纳肛,早、晚各1次。两组均给药8周。采用疾病活动指数(DAI)评价疾病活动程度。以治疗第8周时DAI评分作为主要疗效指标;以治疗第8周时DAI各分项评分(大便次数、大便带血、黏膜炎症、总体评价)及临床缓解率作为次要疗效指标,并记录两组不良反应发生情况。结果患者均完成8周治疗。两组治疗前后DAI评分比较,差异均有统计学意义(P<0.001);两组间治疗前及治疗第8周DAI评分比较,差异均无统计学意义(P>0.05)。A组治疗第8周时DAI评分-B组治疗第8周时DAI评分(U1-U2)双侧95%可信区间(-0.33,0.87)的下限>-1.00,拒绝无效假设,认为A组的疗效不差于B组。两组治疗8周后大便次数、大便带血、黏膜炎症、整体评价评分均低于治疗前,差异有统计学意义(P<0.05)。治疗前和治疗第8周,两组间大便次数、大便带血、黏膜炎症、整体评价评分比较,差异均无统计学意义(P>0.05)。经过8周治疗后,A、B两组临床缓解率分别为95.1%(39/41)、90.2%(37/41),差异无统计学意义(χ2=0.719,P=0.396)。A组不良反应发生率为48.8%(20/41),B组不良反应发生率为61.0%(25/41),差异无统计学意义(χ2=1.231,P=0.267)。结论在8周的临床试验中,美沙拉秦栓1.0 g 1次/d给药与0.5 g 2次/d给药治疗轻中度活动期溃疡性直肠炎疗效一致,且安全。
基金Supported by Academician Jie-Shou Li Intestinal Barrier Research Foundation,No.LJS_201008
文摘AIM To investigate the changes in microbiota in feces of patients with ulcerative colitis(UC) and pouchitis using genomic technology.METHODS Fecal samples were obtained from UC patients with or without an ileal pouch-anal anastomosis(IPAA) procedure, as well as healthy controls. The touchdown polymerase chain reaction technique was used to amplify the whole V3 region of the 16 S r RNA gene, which was transcribed from DNA extracted from fecal samples. Denaturing gradient gel electrophoresis was used to separate the amplicons. The band profiles and similarity indices were analyzed digitally. The predominant microbiota in different groups was confirmed by sequencing the 16 S rR NA gene. RESULTS Microbial biodiversity in the healthy controls was significantly higher compared with the UC groups(P < 0.001) and IPAA groups(P < 0.001). Compared with healthy controls, the UC patients in remission and those in the mildly active stage, the predominant species in patients with moderately and severely active UC changed obviously. In addition, the proportion of the dominant microbiota, which was negatively correlated with the disease activity of UC(r =-6.591, P < 0.01),was decreased in pouchitis patients. The numbers of two types of bacteria, Faecalibacterium prausnitzii and Eubacterium rectale, were reduced in UC. Patients with pouchitis had an altered microbiota composition compared with UC patients. The microbiota from pouchitis patients was less diverse than that from severely active UC patients. Sequencing results showed that similar microbiota, such as Clostridium perfringens, were shared in both UC and pouchitis.CONCLUSION Less diverse fecal microbiota was present in patients with UC and pouchitis. Increased C. perfringens in feces suggest its role in the exacerbation of UC and pouchitis.
文摘目的探索复方甘草酸苷注射液联合复方谷氨酰胺肠溶胶囊治疗溃疡性结肠炎的临床疗效。方法选取2014年2月—2017年4月西安市中医医院收治的124例溃疡性结肠炎患者,随机分为对照组和治疗组,每组各62例。对照组口服复方谷氨酰胺肠溶胶囊,4粒/次,3次/d。治疗组患者在对照组治疗基础上静脉滴注复方甘草酸苷注射液,20 m L/次加入到生理盐水500 m L中,1次/d。两组患者均连续治疗30 d。观察两组的临床疗效,比较两组腹痛程度、疾病活动指数(DAI)、黏液脓血便消失时间。结果治疗后,对照组和治疗组的总有效率分别为82.26%、96.77%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者腹痛程度评分、DAI指数均较治疗前显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组腹痛程度评分、DAI指数均低于对照组,两组比较差异具有统计学意义(P<0.05);治疗组黏液脓血便消失时间显著短于对照组,两组比较差异具有统计学意义(P<0.05)。结论复方甘草酸苷注射液联合复方谷氨酰胺肠溶胶囊治疗溃疡性结肠炎具有较好的临床疗效,可显著降低腹痛程度,降低DAI指数,具有一定的临床推广应用价值。
